Tous Actualités
Suivre
Abonner Helsinn Healthcare SA

Helsinn Healthcare SA

A top-gear drug for the treatment of pain and inflammation

Lugano (ots)

New evidences confirm the assets of Original
Nimesulide(1): multifactorial pharmacological activity, fast
analgesic action, proven clinical efficacy
Presented at Helsinn Satellite Symposium
"A valuable common approach to the treatment of different pain
conditions "
12th International Pain Clinic Congress 2006, World Society of
Pain Clinicians
Turin (Italy), 4-7 July 2006
New evidences highlighting the active role played by Original
Nimesulide(1) on some key mediators involved in painful and
inflammatory processes were brought for the first time to the
attention of the scientific universe at Helsinn Satellite Symposium
held during the 12th International Pain Clinic Congress organized by
the World Society of Pain Clinicians in Turin (Italy) from 4 to 7
July last.
The Congress was the right occasion to take stake of the efficacy,
rapidity of action and tolerability of Original Nimesulide(1) in
three major fields of application: osteoarthritis, post-operative
dental pain and migraine.
Clinical validations presented at the Congress
Nimesulide and OA inflammatory pain: new clinical
evidence Epidemiological data are impressive: >36 million people in
Europe suffer from osteoarthritis.
In the study presented by Prof. Bianchi comparing the analgesic
efficacy of nimesulide and celecoxib in patients with knee OA, the
effect of Original Nimesulide(1) was significantly faster than
celecoxib and its activity was stronger in patients with synovial
effusion. The clinical efficacy of our drug was associated with a
reduction in the concentration of Substance P (SP) and Interleukin-6
(IL-6) in the synovial fluid, thus at the site of inflammation. SP
and IL-6 represent key mediators of pain and inflammation, and by
reducing their concentration, Original Nimesulide is able to decrease
the intensity of pain vs. the reference drug.
Further to this, Original Nimesulide acts on "centrally active"
prostaglandins, which play a primary role in the transmission of the
pain signal not only at peripheral level but also at central nervous
system level, with particular reference to the spinal marrow.
Interleukins represent not only the "alphabetical characters" that
endocrine and immune nervous cells use to communicate, but are
crucial mediators in the modulation of the nociceptive information.
Substance P (SP) is a small neuropeptide characterised by a peculiar
activity: it was observed that, following stimulation of the
peripheral nerves that are activated by painful stimuli, SP follows a
path from the centre towards the periphery amplifying pain and
inflammation.
Nimesulide and dental pain: results from an
observational study
The analgesic effect of Original Nimesulide(1) is already evident
just 15 minutes after drug in-take and grants a significant reduction
of pain following third molar extraction.
Surgery involving dental extraction generally represents a good
model to evaluate the analgesic efficacy of a drug. Dr. Lorincz
presented the results of an observational study involving 511
patients undergoing surgical third molar removal (Abstracts from the
Symposium). The results indicate that Original Nimesulide(1) grants
complete resolution of pain in 74% of patients against 57% of
patients treated with other NSAIDs. The study further confirms the
rapid onset of the analgesic effect of the drug that acts within 15
minutes from its administration in 67% of patients, as well as its
very good safety profile.
C. Lampl - Insights on the use of nimesulide in migraine attacks
80 million people suffer from migraine in Western countries. The
WHO positions it among the top 20 causes for disability.
Dr. Lampl provided an overview on the therapeutic alternatives for
the treatment of migraine, underlining the key role played by NSAIDs,
with particular reference to the efficacy of Original Nimesulide(1)
in the treatment of pain in migraine attacks (Abstracts from the
Symposium).
Various clinical evidences are available on the efficacy of
Original Nimesulide(1) in the treatment of this kind of pain. Results
from an epidemiological study interestingly highlighted that approx.
one patient out of three among those visited for the first time in
Italian specialised headache centres were prescribed Original
Nimesulide(1).
Conclusions
In conclusion, Original Nimesulide(1) confirms through several new
evidences its up-to-dateness both from a pharmacological (activity on
pain transmission mediators) and a clinical (rapid analgesic effect)
point of view.
Its characteristics comply perfectly with the current needs for
the treatment of various types of acute pain. In particular, the WSPC
Congress was the right opportunity to present the new data on
osteoarticular pain, post-operative dental pain and migraine.
Helsinn, holder of the international rights on the Original
Nimesulide(1) molecule, grants the manufacturing of the active
ingredient according to very high qualitative standards, in
compliance with international GMP rules, in its plants in Switzerland
and Ireland. By following the product throughout its market
life-cycle, Helsinn guarantees constant scientific support through
continuous clinical and pharmacological studies carried out in
various countries.
This is why Original Nimesulide(1) keeps on being an up-to-date
product holding the spotlight of the international scientific
community through its presence at the WSPC Congress 2006.
(1) Original Nimesulide is available world-wide under the
following trademarks: Ainex, Aulin, Donulide, Edrigyl, Eskaflam,
Heugan, Mesulid, Nexen, Nimed, Nimedex, Nisulid, Scaflam, Scaflan

Contact:

Contact person at HELSINN, Switzerland
Massimo Tosi, M. Chem. Pharm.,
Senior Manager, Head of Marketing Services,
Commercial Operations
Phone +41/91/985'21'21
E-Mail: info-hhc@helsinn.com

Plus de actualités: Helsinn Healthcare SA
Plus de actualités: Helsinn Healthcare SA